An antitrust lawsuit is seeking to stop Actavis from forcing Alzheimer’s patients to switch medications to maintain high drug prices.
The switch would disrupt patient treatment and restrict patient choice just to protect corporate profits, New York Attorney General Attorney Eric T. Schneiderman said Tuesday.
Actavis has announced a plan to withdraw its Alzheimer’s drug Namenda from the market.
A patent that protects Namenda will expire in July of 2015 , and the company will then face competition from generic drug makers. Instead, Actavis plans to force patients to switch to a similar drug with a longer patent.